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Objectives. This study sought to determine whether neurohor- 
monal activation occurs in isolated right heart failure. 
Background. Neurohormonai activation appears to parallel the 
severity of left heart failure, but little is known about its role in 
right heart failure. 
Methods. We evaluated neurohormonal activation and endothe- 
lin levels in 21 patients with primary pulmonary hypertension at
the time of right heart catheterization. 
Results. Plasma norepinephrine levels correlated significantly 
with pulmonary artery pressure (r = 0.66, p < 0.01), cardiac index 
(r = -0.56, p < 0.01) and pulmonary vascular resistance (r = 
0.69, p < 0.001). Atrial natrinretie peptide levels were higher in 
the pulmonary artery than the right atrium and femoral artery 
and correlated closely with pulmonary artery oxygen saturation 
(r = -0.73, p < 0.0001). Plasma renin levels were not elevated. 
Endothelin levels were increased and correlated with right atrial 
pressure (r = 0.74, p < 0.0001) and pulmonary artery oxygen 
saturation (r = -0.070, p < 0.0004). 
Conclusions. Neurohormonal activation occurs in patients with 
isolated right ventricular failure and inherently normal left 
ventricles and appears to be related to the overall severity of 
cardiopnlmonary derangements. The elevation in endothelin lev- 
els is consistent with its release in response to pulmonary 
hypertension. 
(J Am Coil Cardio11995;26:1581-5) 
The left ventricle has traditionally been the focus of studies 
relating to neurohormonal activation in heart failure that can 
result from isolated left ventricular dysfunction or left ventric- 
ular dysfunction i  combination with right ventricular dysfunc- 
tion (1,2). It has never been possible to determine the relative 
contribution of each ventricle with respect o neurohormonal 
activation, although some recent studies (3) have placed 
greater emphasis on right ventricular function as a predictor of 
outcome in patients with left ventricular failure. 
The present study was undertaken to determine whether 
neurohormonal activation occurs in patients with isolated right 
vcntricular failure and intrinsically normal left ventricular 
function. We hypothesized that if neurohormonal activation 
was observed, it would lead to a better understanding of the 
physiologic signals for such activation. To that end, patients 
with primary pulmonary hypertension represent an ideal pa- 
tient group to study. 
We also investigated the role of endothelin production and 
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release in patients with pulmonary hypertension and right 
ventricular failure. Endothelin levels have recently been ob- 
served to be elevated in patients with chronic left ventricular 
failure with secondary (4,5) and primary pulmonary hyperten- 
sion (6). However, how endothelin relates to the hemodynamic 
state or to other neurohormones in primary pulmonary hyper- 
tension has not yet been clarified. 
Methods  
Study patients. Twenty-one consecutive patients with pri- 
mary pulmonary hypertension referred to the University of 
Illinois at Chicago were entered into the study (14 women, 7 
men; mean [_+SD] age 41 _+ 13 years, range 15 to 58). All 
patients were evaluated by clinical history, physical examina- 
tion, chest radiography, perfusion lung scanning, pulmonary 
function testing, echocardiography and right heart cardiac 
catheterization. Secondary causes of pulmonary hypertension 
were excluded on the basis of criteria used by the National 
Institutes of Health (NIH) registry on primary pulmonary 
hypertension (7). Normal left ventricular function was docu- 
mented in every patient by echocardiography. All patients had 
a complete chemistry profile to exclude hepatic or renal 
dysfunction. The study protocol was approved by the Univer- 
sity of Illinois Institutional Review Board before patient entry. 
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Hemodynamic studies. All vasoactive medications were 
withheld for at least 48 h before the study. All patients 
underwent diagnostic right heart catheterization after an over- 
night fast. Right atrial, pulmonary artery and pulmonary 
capillary wedge pressures and cardiac output (in triplicate) 
were determined using a flow-directed thermodilution catheter 
advanced into the pulmonary artery through the femoral veins. 
Systemic arterial pressure was determined by means of a small 
cannula in the femoral artery. Pulmonary and systemic vascular 
resistance values were calculated according to standard formu- 
las. 
Sample collection. After collection of hemodynamic data, 
the patients were moved to a quiet room and allowed to rest in 
a supine position for 30 rain. Blood samples were drawn 
simultaneously from the thcrmodilution catheter and the fem- 
oral cannula from three sites: pulmonary artery, right atrium 
and femoral artery. Blood samples for plasma norepinephrine 
were placed in prechilled (Amersham) collection tubes con- 
taining ethyleneglycoltetraacetic acid (EGTA) and glutathi- 
one, and blood samples for plasma renin activity, atrial natri- 
uretic peptide and endothelin level determinations were 
placed in tubes containing ethylenediaminetetraacetic acid 
(EDTA) at room temperature. All samples, except plasma 
renin activity, were placed on ice immediately after collection 
and then centrifuged at 2,500 rpm for 12 min at 4°C. The 
plasma was then transferred to 12 x 75-ram polypropylene 
tubes and frozen upright at -70°C. Samples were shipped on 
dry ice to the University of Minnesota for analysis, within 15 
days of collection. Plasma norepinephrine l vels were mea- 
sured by a radioenzymatic method (Catecholamine Assay Kit, 
Amersham), whereas plasma renin activity, atrial natriuretic 
peptide and endothelin levels were measured by radioimmu- 
noassay. The endothelin assay had the following cross-reactivities: 
endothelin-1 100%; endothelin-2 91%; endothelin-3 0.05%; 
"big" endothelin 76%. 
Survival estimates. To determine whether neurohormonal 
activation might be associated with prognosis, 1-, 2-, 3-, 4- and 
5-year survival was computed for each patient on the basis of 
a formula derived from the data base of the NIH registry on 
primary pulmonary hypertension, which includes cardiac index, 
mean pulmonary artery pressure and mean right atrial pressure 
(8). This formula has been validated in two subsequent clinical 
studies (9,10). 
Statistical methods. Mean values _+ SD were computed for 
all hemodynamic variables. Because the distribution for neu- 
rohormonal measurements was highly skewed, nonparametric 
statistics were used to describe these data as median (25th to 
75th percentile), and to perform statistical tests. Comparisons 
of neurohormonal nd endothelin values from samples drawn 
from the right atrium, pulmonary artery and femoral artery 
sites were made using the Friedman test and the Wilcoxon 
signed-rank test. The neurohormonal nd endothelin values 
obtained from the samples drawn from the pulmonary artery 
site were used for estimating the Spearman correlation coef- 
ficients with the measured hemodynamic data and various 
biochemical tests. One-way analysis of variance was used to 
Table 1. Baseline Hemodynamic Variables in 21 Patients With 
Primary Pulmonary Hypertension 
Mean + SD Range 
Heart rate (beats/min) 86 _+ 16 59-115 
Systemic arterial pressure (mm Hg) 88 _+ 13 56-120 
PA pressure (mm Hg) 56 _+ 15 26-80 
RA pressure (ram Hg) 11 _+ 7 3-30 
Pulmonary capillary wedge pressure (mm Hg) 8 ± 3 3-15 
Cardiac index (liters/min per m 2) t.92 ± 0.54 1.19-3.28 
Systemic vascular resistance (U) 24 _+ 9 9-40 
Pulmonary vascular resistance (U) 16 _+ 8 2-33 
Systemic arterial oxygen saturation (%) 88 _+ 9 62-96 
PA oxy. gen saturation (%) 52 _+ 14 25-71 
PA - ptdmonary artery; RA - right atrial. 
test the differences between groups with respect o expected 
survival rates and levels of plasma norepinephrine; p -< 0.05 
was considered significant without adjustments for multiple 
comparisons. 
Results 
Hemodynamic variables. At catheterization, all 21 patients 
had hemodynamic variables characteristic of primary pulmo- 
nary hypertension (Table 1): Pulmonary artery pressure 
ranged from 26 to 80 mm Hg (mean 56 -+ 15) and pulmonary 
vascular esistance from 2 to 33 U (mean 16 + 8 U). These 
ranges reflected the broad spectrum of severity of primary 
pulmonary hypertension present in this group. 
Neurohormonal values. Median values for plasma norepi- 
nephrine (441 pg/ml) and atrial natriuretic peptide (134 pg/ml) 
obtained from the pulmonary artery were increased in patients 
with primary pulmonary hypertension compared with previ- 
ously established normal values from the same laboratory 
(Table 2). The median value for plasma renin activity was 
similar, but that for endothelin (12.5 pg/ml) was increased, in 
patients with primary pulmonary hypertension compared with 
previously established normal values. 
Neurohormone and endothelin levels assayed from the 
right atrium, pulmonary artery and femoral artery sites were 
also compared (Table 2). Mean levels of atrial natriuretic 
peptide obtained from the pulmonary artery (278 pg/ml) were 
significantly higher (p = 0.0004) than samples from the right 
atrium (235 pg/ml) and tended to be higher than those from 
the femoral artery (239 pg/ml, p = 0.06). However, there were 
no significant differences in values of plasma norepinephrine, 
plasma renin activity, or endothelin obtained from the three 
sites. Correlations between neurohormone and endothelin 
levels and other variables consequently were made between 
the levels obtained from the pulmonary artery site. 
Plasma norepinephrine l vels correlated significantly with 
right atrial pressure (r = 0.61, p < 0.01), pulmonary artery 
pressure (r = 0.66, p < 0.01), cardiac index (r = -0.56, p < 
0.01) and pulmonary artery oxygen saturation (r = -0.55, p < 
0.01). However, the closest correlation was between plasma 
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Table 2. Neurohormonal nd Endothelin Values Obtained From Pulmonary Artery, Right Atrium and 
Femoral Artery in 21 Patients With Primary Pulmonary Hypertension 
Primary Pulmonary Hypertension Normal Values 
PA Site RA Site FA Site Peripheral Vein 
PNE (pg/ml) 441 (315-582) 501 (365-555) 443 (317-515) 255 (21)1-340) 
PRA (pg/ml per hi 2.4 (1.2-3.4) 3.0 (I.6-4.2) 1.9 (1.3-3.9) 3.1 (2.1-5.1) 
ANP (pg/ml) 134 ( I 17-358) 114 (56-332)* 173 (98-353)? 24 (12-32) 
ET (pg/ml) 12.5 (9.5-20.6) 13 (9.5-19.4) 11 (9.3-19.2) 6.9 (6.2-8.2) 
*p = 0.004, ~p = 0.11t~ versus pulmonary, artery (PAl site. Data presented arc median (interquartile range). ANP = 
atrial natriuretic peptide: ET endothelin; FA = femoral artep,' PNE = plasma norepinephrine; PRA = plasma renin 
actMty: RA = right atrial. 
norepinephrine l vels and pulmonary vascular esistance (r - 
0.69, p < 0.001) (Fig. 1). In contrast, atrial natriuretic peptide 
levels correlated most closely with pulmonary artery oxygen 
saturation (r = -0.73, p < 0.0001) (Fig. 2) and to a lesser 
extent with mean right atrial pressure (r -- 0.44, p -- 0.05). 
Correlations were also found between endothelin levels and 
mean right atrial pressure (r = 0.74. p < 0.0001) and pulmo- 
nary artery oxygen saturation (r = -0.70, p < 0.0004) (Fig. 3). 
We also found a correlation between endothelin and atrial 
natriuretic peptide levels (r = 0.54, p = 0.01) and endothelin 
and plasma norepinephrine l vels (r = 0.49, p < 0.01) but not 
between endothelin levels and pulmonary vascular esistance 
(r = 0.25, p = NS). 
Previous studies of left heart failure (I l l  have shown a 
strong relation between plasma norepinephrine l vels and 
patient survival. To test whether a similar relation could be 
found with right heart failure, the present patients were 
classified into three groups according to plasma norepineph- 
rine values: <370 pg/ml (group 1), 370 to 500 pg/ml (group 2) 
and >500 pg/ml (group 3). These values were then used to 
calculate the estimated 5-year survival rate according to the 
NIH registry on primary pulmonary hypertension equation 
predicting survival for patients with primary pulmonary hyper- 
tension (Table 3, Fig. 4). The resulting predicted 5-year 
Figure 1. Individual patient data (circlest show a strong positive 
correlation (r = 0.76, p < 0.0001) between plasma norepinephrine 
(PNE) levels and pulmonary vascular resistance (PVR). Diagonal line: 
y -- 0.01x + 9.05. 
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survival rates were significantly different: 44% for group 1, 
31% for group 2 and 17% for group 3 (p = 0.0009). 
Discussion 
Ncurohormonal ctivation contributes to the development 
of symptoms related to chronic congestive heart failure (12). 
Because neurohormones correlate poorly with one another, it 
is likely that there are multiple mechanisms that cause neuro- 
hormonal activation. Neurohormonal ctivation can alter the 
loading conditions of the heart by increasing impedance and 
blood volume, thus causing further reductions in cardiac 
function (2). The precise physiologic signals that result in 
neurohormonal ctivation are not fully understood but may 
relate to left ventricular stroke volume and left atrial and 
ventricular filling pressures or the effect of cardiac dysfunction 
on the peripheral vasculature (2). It was recently demonstrated 
(3) that patients with biventricular dysfunction have a poorer 
prognosis than those with left ventricular dysfunction only, 
suggesting that right ventricular performance contributes to 
the prognosis of these patients. Whether this relates to neuro- 
hormonal activation has not been explored. 
Present study. We studied neurohormonal ctivation in 
patients with primary pulmonary hypertension because such 
Figure 2. Atrial natriuretic peptide (ANP) levels and pulmonary 
artery oxygen saturation (PA 02 SAT) show a strong negative corre- 
lation (r = -0.65, p < 0.001). Format as in Figure 1. 
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Figure 3. Endothelin (ET) levels and pulmonary artery oxygen satu- 
ration (PA 0 2 SAT) show a strong negative correlation (r = -0.71, 
p < 0.0003). Format as in Figure 1. 
patients have right ventricular dysfunction in the presence of 
normal eft ventricular performance. The present study showed 
that neurohormonal ctivation occurs in patients with primary 
pulmonary hypertension and significantly relates to the severity 
of hemodynamic dysfunction. Furthermore, neurohormonal 
activation is strongly related to pulmonary arterial oxygen 
saturation, a physiologic manifestation of the severity of heart 
failure that has not been fully explored in studies of left heart 
failure. These findings suggest hat the signals for neurohor- 
monal activation are not solely confined to the left side of the 
heart and may relate more to the overall level and nature of 
cardiopulmonary abnormalities than any single physiologic 
disturbance. 
Neurohormonal values were similar when sampled from the 
right atrium, pulmonary artery and femoral artery, with the 
exception of those for atrial natriuretic peptide, which was 
higher in the pulmonary artery. This finding is consistent with 
the observation of atrial natriuretic peptide release from the 
right atrium in these patients (13). The lack of plasma renin 
activity level elevation may be a function of the small number 
of patients with severe right ventricular failure and systemic 
venous congestion, but further investigation is warranted. 
Endothelin, a product of endothelial cells, has been shown 
to have elevated levels in patients with congestive heart failure 
and secondary and primary pulmonary hypertension (4,5). 
Although endothelin has several biologic effects, one major 
activity appears to relate to vasoconstriction a d the mainte- 
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Figure 4. Estimated survival of patients according to plasma norepi- 
nephrine (PNE) levels: squares = <370 ng/ml; triangles = 370 to 
500 ng/ml; circles = >500 ng/ml. Patients with the highest levels of 
plasma norepinephrine are projected to have the poorest prognosis. 
nance of blood pressure (14). Elevated endothelin levels in 
pulmonary hypertension has been suggested as indicating a 
role for endothelin in the pathophysiology or maintenance of
pulmonary hypertension i several disease states (6). 
It has been difficult to determine whether endothelin is 
related more to the cause or the effect of primary pulmonary 
hypertension. The elevation of endothelin levels seen in sec- 
ondary forms of pulmonary hypertension suggests that it is a 
response to physiologic signals from the pulmonary vascular 
endothelium. However, the finding of elevated levels in the 
neonatal fawn hooded rat, an animal that develops pontane- 
ous pulmonary hypertension, suggests that it may also be 
causative in pulmonary hypertensive states as well (15). The 
relation between endothelin and neurohormonal levels in 
the present study suggests that endothelin release is related to 
the cardiovascular physiologic state of the patient. The signals 
for endothelin production and release remain unclear, but the 
correlation of endothelin levels with pulmonary artery oxygen 
saturation, and not pulmonary vascular resistance, suggests 
that endothelin might not be directly involved in determining 
pulmonary vascular tone in primary pulmonary hypertension. 
Prostacyclin and thromboxane l vels may also be related to 
neurohormonal ctivation in primary pulmonary hypertension, 
but these were not measured in the present study (16). 
We explored the possibility that the level of neurohormonal 
activation in patients with primary pulmonary hypertension 
may be related to survival, as has been described in patients 
with chronic congestive heart failure (11). By classifying our 
Table 3. Estimated Percent Survival (mean _+ SD) Over 5 Years for 21 Patients With Primary 
Pulmonary Hypertension 
PNE Love] 
(pg, ml) 1 yr 2 yr 3 yr 4 yr 5 yr 
<370 0.74 - 0.12 0.63 + (I.14 0.55 -+ 0.16 0.48 _+ 0.16 0.44 _+ 0.15 
370-500 0.66 ~ 0.09 0.53 _+ 0.11 I).43 _+ 0.12 0.36 _+ 0.12 0.31 _+ 0.11 
>500 0.51 + 0.16 (I.36 + 0.16 0.27 _+ 0.14 0.21 _+ 0.11 0.17 _+ 0.10 
PNE plasma norepinephrine. 
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patients into three groups according to plasma norepinephrine 
levels, we were able to demonstrate different predicted survival 
rates, raising the possibility that neurohormonal ctivation may 
be a determining factor for survival in primary pulmonary, 
hypertension as it is in congestive left heart failure. 
Study limitations. Although we were able to study patients 
with a wide range of hemodynamic derangements, the rela- 
tively small number of patients limits our ability to define these 
relations with precision. In addition, the endothelin assay used 
detects everal forms that may have diminished the specificity 
of the observations. Finally, although the equation developed 
to predict survival in patients with primary, pulmonary, hyper- 
tension has been validated in two subsequent studies, the 
prognostic value of plasma norepinephrine l vels remains 
speculative and may be an indirect reflection of hemodynamic 
variables rather than an independent factor. 
Conclusions. Patients with isolated right ventricular dys- 
function from primary pulmonary, hypertension and inherently 
normal left ventricles appear to have neurohormonal ctiva- 
tion that relates to the severity of their hemodynamic derange- 
ment. This finding suggests that the signals for neurohormonal 
activation do originate from a specific chamber in the heart: 
rather, they are related to the physiologic state of the patient 
and the interplay of factors that determine cardiovascular 
performance. Neurohormonal ctivation may be a marker of 
prognosis in these patients and may provide another focus for 
the long-term treatment of prima U pulmona~' hypertension. 
We thank Jay N. Cohn, MD. in whose laboratories the measurements were 
made, for support of this study. 
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